Lymphoma: Pembrolizumab treatment approved

Share This Post

On June 12-13, FDA approved two new indications for K drug, just the day before the K drug was approved for the treatment of cervical cancer. One day later, the US FDA approved pembrolizumab (Keytruda, pembrolizumab) for the treatment of adults and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL) who had relapsed after at least two lines of treatment .

The approval was based on data from 53 patients with relapsed or refractory PMBCL from the multicenter, open label, single arm trial KEYNOTE-170 (NCT02576990). Patients received 200 mg of Pembrolizumab intravenously every 3 weeks until unacceptable toxicity or disease progression, or up to 24 months for patients who did not progress. The overall effective rate is 45%, including 11% complete remission and 34% partial remission. During the follow-up period (median was 9.7 months), the median response time was not reached. The median time for the first objective response was 2.8 months. Pembrolizumab is not recommended for patients with PMBCL who require emergency tumor reduction.

In KEYNOTE-170, the most common adverse reactions in patients with ≥10% PMBCL are musculoskeletal pain, upper respiratory tract infection, fever, fatigue, cough, dyspnea, diarrhea, abdominal pain, nausea, arrhythmia and headache. Pembrolizumab was discontinued or discontinued due to adverse reactions in 8% and 15% of patients, respectively. 25% of patients had adverse reactions requiring systemic corticosteroid treatment, and 26% of patients had serious adverse reactions.

https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm610670.htm

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

After amazing growth of CAR T-Cell therapy what's next
CAR T-Cell therapy

After amazing growth of CAR T-Cell therapy: what’s next?

CAR T-cell therapy has rapidly transformed cancer treatment by reprogramming a patient’s T-cells to attack cancer cells, demonstrating remarkable success in hematologic cancers. Advances in genetic engineering, regulatory support, and investment are driving further expansion. Researchers are now tackling the challenges of applying this therapy to solid tumors, aiming to enhance efficacy and accessibility, marking a new era in personalized cancer therapy and immunotherapy.

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS
Cancer

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy